Codiak BioSciences, Inc. reports results for the quarter ended in December - Earnings Summary

Codiak BioSciences,.

15/03/2022 13:32

* Codiak BioSciences, Inc.  CDAK.OQ  reported a quarterly
adjusted
loss of 74 cents​​ per share for the quarter ended in December.
The mean expectation of three analysts for the quarter was for a
loss of 94 cents per share.
    * Revenue rose 369.6% to $7.70 million from a year ago; 
analysts
expected $1.51 million. 
    * Codiak BioSciences, Inc.'s reported EPS for the quarter
was 74
cents​.
    * The mean earnings estimate of analysts had fallen by
about 2% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Codiak BioSciences, Inc. shares had fallen by 57.7% this
quarter.
    * The company reported quarterly net income of $16.66
million.
    * Wall Street's median 12-month price target for Codiak
BioSciences, Inc. is $21.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated March 15 at 01:32 p.m.  ​All
figures in US dollars unless otherwise stated